A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to
 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.
Inclusion Criteria:

 -  Participants must have a history of migraine with or without aura as defined by
 International Headache Society International Classification of Headache Disorders, 3rd
 edition (ICHD-3) (ICHD-3 2018) diagnostic criteria 1.1 or 1.2.1 and meets the
 following criteria:

 -  History of migraine attacks for more than 6 months

 -  Reports at least 2 and no more than 8 moderate-to-severe migraine attacks per
 month in the 2 months prior to screening visit

 -  Duration of a typical untreated migraine attack (excluding sleep) is greater than
 or equal to 3 hours

 -  Participant has not, by history, experienced satisfactory response with a
 previous migraine therapy, in the opinion of the investigator

 -  Participant must be able to swallow a tablet

 -  For participants taking migraine preventive medication, treatment regimen is stable
 and has been taken for at least 3 months prior to screening

 -  Participants must weigh at least 15 kilograms (kg)

 Exclusion Criteria:

 -  Participants must not be pregnant or nursing

 -  Participants must not have any acute, serious, or unstable medical condition

 -  Participants must not be actively suicidal or at significant risk for suicide, in the
 opinion of the investigator